Online inquiry

IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11566MR)

This product GTTS-WQ11566MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD276 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001024736.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 80381
UniProt ID Q5ZPR3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ11566MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3175MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AR-101
GTTS-WQ5596MR IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDP7766
GTTS-WQ5911MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CIM 331
GTTS-WQ3819MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BB-10901
GTTS-WQ232MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ7184MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ3362MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AT-004
GTTS-WQ6086MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO-1959
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW